A pharmacological study in the kindling model of epilepsy

Timothy E Albertson, R. M. Joy, L. G. Stark

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The anticonvulsant properties of carbamazepine were evaluated in the kindled amygdaloid seizure model in rats. Carbamazepine significantly raised the threshold for seizures, reduced the duration of elicited afterdischarges and attenuated the severity of seizures in previously-kindled rats, at doses that did not cause sedation or ataxia. A similar reduction in the duration of elicited afterdischarges and severity of seizures was seen after suprathreshold stimulation (400 μA) with doses of carbamazepine that were without obvious sedative or ataxic effects. After acute intraperitoneal injections (solvent = 2% Tween-80 and70% propylene glycol), the maximum anticonvulsant effectiveness against suprathreshold stimulation was seen at 30 min. When administered daily (13 days) during acquisition or development of kindling, carbamazepine (25 and 50 mg/kg, i.p.) had variable effects on kindling. Neither dose consistently reduced the duration of elicited afterdischarges during the acquisition phase. Both groups tended to reduce the developing seizure, with the smaller dose of carbamazepine (25 mg/kg) resulting in a more consistent and significant reduction in severity of seizures. No significant differences in number of daily stimulations needed to reach fully kindled seizures were found. Previous studies have reported variable results with carbamazepine and the kindled amygdaloid seizure in rats. The present study provides a comprehensive evaluation of carbamazepine in this model of epilepsy and discusses the results with regard to the findings reported previously.

Original languageEnglish (US)
Pages (from-to)1117-1123
Number of pages7
JournalNeuropharmacology
Volume23
Issue number10
DOIs
StatePublished - 1984

Fingerprint

Carbamazepine
Epilepsy
Seizures
Pharmacology
Anticonvulsants
Propylene Glycol
Polysorbates
Ataxia
Intraperitoneal Injections
Hypnotics and Sedatives

Keywords

  • amygdala
  • carbamazepine
  • epilepsy
  • kindled
  • kindling
  • seizure threshold

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

A pharmacological study in the kindling model of epilepsy. / Albertson, Timothy E; Joy, R. M.; Stark, L. G.

In: Neuropharmacology, Vol. 23, No. 10, 1984, p. 1117-1123.

Research output: Contribution to journalArticle

Albertson, Timothy E ; Joy, R. M. ; Stark, L. G. / A pharmacological study in the kindling model of epilepsy. In: Neuropharmacology. 1984 ; Vol. 23, No. 10. pp. 1117-1123.
@article{ea9ab122101e4dd09a30db34acccbfac,
title = "A pharmacological study in the kindling model of epilepsy",
abstract = "The anticonvulsant properties of carbamazepine were evaluated in the kindled amygdaloid seizure model in rats. Carbamazepine significantly raised the threshold for seizures, reduced the duration of elicited afterdischarges and attenuated the severity of seizures in previously-kindled rats, at doses that did not cause sedation or ataxia. A similar reduction in the duration of elicited afterdischarges and severity of seizures was seen after suprathreshold stimulation (400 μA) with doses of carbamazepine that were without obvious sedative or ataxic effects. After acute intraperitoneal injections (solvent = 2{\%} Tween-80 and70{\%} propylene glycol), the maximum anticonvulsant effectiveness against suprathreshold stimulation was seen at 30 min. When administered daily (13 days) during acquisition or development of kindling, carbamazepine (25 and 50 mg/kg, i.p.) had variable effects on kindling. Neither dose consistently reduced the duration of elicited afterdischarges during the acquisition phase. Both groups tended to reduce the developing seizure, with the smaller dose of carbamazepine (25 mg/kg) resulting in a more consistent and significant reduction in severity of seizures. No significant differences in number of daily stimulations needed to reach fully kindled seizures were found. Previous studies have reported variable results with carbamazepine and the kindled amygdaloid seizure in rats. The present study provides a comprehensive evaluation of carbamazepine in this model of epilepsy and discusses the results with regard to the findings reported previously.",
keywords = "amygdala, carbamazepine, epilepsy, kindled, kindling, seizure threshold",
author = "Albertson, {Timothy E} and Joy, {R. M.} and Stark, {L. G.}",
year = "1984",
doi = "10.1016/0028-3908(84)90227-2",
language = "English (US)",
volume = "23",
pages = "1117--1123",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - A pharmacological study in the kindling model of epilepsy

AU - Albertson, Timothy E

AU - Joy, R. M.

AU - Stark, L. G.

PY - 1984

Y1 - 1984

N2 - The anticonvulsant properties of carbamazepine were evaluated in the kindled amygdaloid seizure model in rats. Carbamazepine significantly raised the threshold for seizures, reduced the duration of elicited afterdischarges and attenuated the severity of seizures in previously-kindled rats, at doses that did not cause sedation or ataxia. A similar reduction in the duration of elicited afterdischarges and severity of seizures was seen after suprathreshold stimulation (400 μA) with doses of carbamazepine that were without obvious sedative or ataxic effects. After acute intraperitoneal injections (solvent = 2% Tween-80 and70% propylene glycol), the maximum anticonvulsant effectiveness against suprathreshold stimulation was seen at 30 min. When administered daily (13 days) during acquisition or development of kindling, carbamazepine (25 and 50 mg/kg, i.p.) had variable effects on kindling. Neither dose consistently reduced the duration of elicited afterdischarges during the acquisition phase. Both groups tended to reduce the developing seizure, with the smaller dose of carbamazepine (25 mg/kg) resulting in a more consistent and significant reduction in severity of seizures. No significant differences in number of daily stimulations needed to reach fully kindled seizures were found. Previous studies have reported variable results with carbamazepine and the kindled amygdaloid seizure in rats. The present study provides a comprehensive evaluation of carbamazepine in this model of epilepsy and discusses the results with regard to the findings reported previously.

AB - The anticonvulsant properties of carbamazepine were evaluated in the kindled amygdaloid seizure model in rats. Carbamazepine significantly raised the threshold for seizures, reduced the duration of elicited afterdischarges and attenuated the severity of seizures in previously-kindled rats, at doses that did not cause sedation or ataxia. A similar reduction in the duration of elicited afterdischarges and severity of seizures was seen after suprathreshold stimulation (400 μA) with doses of carbamazepine that were without obvious sedative or ataxic effects. After acute intraperitoneal injections (solvent = 2% Tween-80 and70% propylene glycol), the maximum anticonvulsant effectiveness against suprathreshold stimulation was seen at 30 min. When administered daily (13 days) during acquisition or development of kindling, carbamazepine (25 and 50 mg/kg, i.p.) had variable effects on kindling. Neither dose consistently reduced the duration of elicited afterdischarges during the acquisition phase. Both groups tended to reduce the developing seizure, with the smaller dose of carbamazepine (25 mg/kg) resulting in a more consistent and significant reduction in severity of seizures. No significant differences in number of daily stimulations needed to reach fully kindled seizures were found. Previous studies have reported variable results with carbamazepine and the kindled amygdaloid seizure in rats. The present study provides a comprehensive evaluation of carbamazepine in this model of epilepsy and discusses the results with regard to the findings reported previously.

KW - amygdala

KW - carbamazepine

KW - epilepsy

KW - kindled

KW - kindling

KW - seizure threshold

UR - http://www.scopus.com/inward/record.url?scp=0021705140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021705140&partnerID=8YFLogxK

U2 - 10.1016/0028-3908(84)90227-2

DO - 10.1016/0028-3908(84)90227-2

M3 - Article

C2 - 6521848

AN - SCOPUS:0021705140

VL - 23

SP - 1117

EP - 1123

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 10

ER -